Key result
Anticoagulants, particularly heparin and coumarin compounds, are the mainstay of prophylaxis for venous thromboembolism, a complication responsible for 50,000 deaths annually.
Anticoagulants remain the primary medical therapy for the prevention and management of venous thromboembolism.
No takes yet. Share an insight, caveat, or question.
Supports anticoagulant prophylaxis for VTE in practice; leaves open optimal integration of newer agents pending prospective trials.
Stanford Wessler (1976) conducted a review in Venous thromboembolism. Anticoagulants (heparin and coumarin compounds) was evaluated. Anticoagulants, particularly heparin and coumarin compounds, are the mainstay of prophylaxis for venous thromboembolism, a complication responsible for 50,000 deaths annually.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: